Abstract
Children with Down Syndrome are at high risk for developing B cell precursor acute lymphoblastic leukemia (DS-ALL) associated with poor outcome due to both a high relapse rate and increased treatment related mortality (TRM) from infections.
Biologically, these heterogeneous leukemias are characterized by underrepresentation of the common cytogenetic subgroups of childhood ALL and overrepresentation of CRLF2-IL7R-JAK-STAT activating genetic aberrations.
Although relapse is the major determinant of poor outcomes in this population, deescalation of chemotherapy intensity might be feasible in the 10-15% DS-ALL patients with ETV6-RUNX1 or high hyperdipoidy in whom TRM is the major limiting event. As infection associated TRM occurs during all treatment phases, including the maintenance period, increased surveillance and supportive care is required throughout therapy. Improvement in outcome will require better understanding of the causes of treatment failure and TRM, incorporation of new therapies targeting the unique biological properties of DS-ALL and enhanced supportive care measures to reduce the risk of infection-related TRM. To facilitate these goals, an international collaboration plans to establish a prospective DS-ALL registry and develop specific supportive care recommendations for this at-risk population.
For personal use only. on April 12, 2017. by guest www.bloodjournal.org From Children with Down Syndrome (DS) are at an increased risk for development of both acute myeloid and lymphoid leukemias (DS-ML and DS-ALL, respectively) [1] [2] . While DS-ML is highly curable, the prognosis of DS-ALL is relatively poor compared to the excellent outcomes for ALL in children without DS 3 .
The following cases highlight several aspects of the diagnosis and management of Down syndrome ALL: While the occurrence of both AML and ALL in the same DS patient is quite rare and reflect the increased risk of both types of leukemias in DS, the rest of the course of the first child reflects many of the typical issues encountered in children with DS-ALL.
The leukemia is typical B cell precursor but usually with normal karyotype lacking any of the usual genetic aberrations of childhood ALL. It often responds poorly to therapy and thus is classified as high risk. This child generally tolerated intensive therapy quite well, however he suffered excess toxicity during maintenance that necessitated therapy modification. The girl in the second case depicts the rarer child with standard risk ALL, based on excellent MRD response. She suffered life endangering toxicity during the initial intensive phase of therapy. The third case illustrates the association of DS-ALL with specific cytogenetic abnormalities, and highlights the challenges in managing TRM in relapsed DS-ALL despite aggressive supportive care.
For personal use only. on April 12, 2017. by guest www.bloodjournal.org From Notwithstanding the poorer prognosis of DS-ALL compared with ALL in children without DS (NDS-ALL), it is important to stress that like the first two patients, the majority of children with DS-ALL are cured. Together these three cases depict the challenges in treatment of ALL in children with DS. It is a delicate balancing act between the need for intensive chemotherapy and the markedly increased toxicity of such therapy. Questions about the risks and benefits of intensive chemotherapy, despite the anticipated toxicity, and the role of reductions in therapy are constantly raised.
Here we will provide some guidelines to assist clinicians in dealing with these questions by reviewing recent data on the biology of this disease and the clinical course of children with DS-ALL treated with contemporary protocols. (table 1) The risk of ALL in children with DS is about 20 fold higher compared to children without DS 2 and children with DS comprise 2-3% of all children enrolled on prospective treatment protocols of ALL 6 . The epidemiology of DS-ALL is very different from DS-ML. While transient myeloid neoplasms are present at birth in about 5% of all DS infants, and full blown DS-ML usually develops before the age of 4 yrs 3 , infant ALL is extremely rare in DS 7-8 . In fact, the peak age of ALL is slightly higher than in children without DS and age of diagnosis extends into adolescents and young adulthood.
Epidemiology and Genetics
Another striking feature of DS-ALL is the almost complete absence of T-ALL. In the recent study conducted by the Ponte Di Legno working group on childhood ALL 7 (herein PdL study), only 5 patients among 708 DS-ALL patients had T-ALL compared with the 10-15% expected rate. Thus the increased risk of ALL in DS is limited to the B cell precursor phenotype. Interestingly, acquired polysomy of chromosome 21 is also found mainly in B cell precursor ALL in children without DS (NDS-ALL), for example in the hyperdiploid phenotype 9 .
The myeloid leukemia of DS is a unique syndrome characterized by an acquired mutation in the GATA1 transcription factor which is encoded by a gene on chromosome X in virtually all cases 3 . In contrast, DS-ALL is not a single biologic entity. This heterogeneity is confirmed by both gene expression and cytogenetic analyses [10] [11] . The common cytogenetic subgroups of childhood NDS-ALL are less common in DS 7, 10 . Approximately 15% of DS-ALLs are positive for the ETV6-RUNX1 Thus, while no unique genetic aberrations have been identified in DS-ALL to date, the distribution of the cytogenetic subgroups is markedly different from NDS-ALL.
Host factors are also altered, as all the normal blood and body cells of DS patients contain a trisomy of chromosome 21. These differences in the biology of the disease and the host impact the clinical course.
Clinical course.

Relapse risk
In sharp contrast to the excellent prognosis of the myeloid leukemias of DS, the prognosis of children with DS-ALL is significantly worse than children without DS 7, [20] [21] [22] [23] [24] [25] [26] [27] . Consequently the median doses of these medications were 25% lower for children with DS compared with NDS patients. Other studies [7] [8] reported that about 40% of DS patients underwent dose reductions during specific protocol courses, especially during high dose MTX blocks. Thus it is possible that reduction of therapy caused by the concerns of increased toxicity contributed to relapses in some DS-ALL patients.
However, the notion that the biological properties of the leukemias also play a major role in determining resistance to therapy is supported by cellular in-vitro cytotoxicity assays demonstrating relative resistance of DS-ALL blasts to a variety of chemotherapeutic agents 28 .
Taken together these observations suggest that some children with DS-ALL may benefit from intensified chemotherapy and that physicians need to be careful in reducing treatment intensity. The immunodeficiency of DS is complex and incompletely understood (reviewed in [35] [36] ). Several immune regulatory and developmental genes such as those encoding the interferon alpha and gamma receptors, AIRE, the suppressors of the NFAT pathway (RCAN and DYRK1A), RUNX1, mir125b, and more are located on chromosome 21. Mild to moderate T cell dysfunction was also reported in children with DS. The NFATCalcineurin pathway is a major regulator of T cell development and function and is inhibited in DS due to the increased dosage of . This is the same pathway that is targeted by the immunosuppressants cyclosporine and tacrolimus. It is also tempting to speculate that the rarity of T-ALL in DS is also possibly due to the block in the NFAT pathway. The major T cell defect has been recently shown to be in decreased thymic output of new T cells, as reflected by reduced T cell receptor excision circles (TREC) 51 . These immunodeficiencies are reflected in increased susceptibility to severe respiratory infections and bacteremias in non-leukemic children with DS
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Current treatment approaches
In an attempt to reduce the excess treatment associated morbidity and mortality, a majority of cooperative groups presently modify the treatment for DS-ALL patients as revealed in a survey of 20 national study groups (personal communication, AV). To date, treatment is stratified by MRD response by all groups surveyed. All groups limit exposure to high doses of intravenous methotrexate by adopting a dose capping (500 mg/m 2 -1000 mg/m 2 with folinic acid rescue) or a cautious dose escalation strategy (starting dose 500-2000 mg/m 2 ). None of the groups give cranial radiotherapy to patients with DS-ALL. NOPHO (Nordic), UKALL and COG limit the use of anthracycline in induction to patients with a slow morphological marrow response (> 25% blasts) at day 15 of a 3 drug regimen (steroid, vincristine and pegylated asparaginase). DCOG (Dutch) and FRALLE (French) groups avoid exposure to induction anthracyclines in all DS patients whereas AIOEP-BFM (ItalianGerman consortium) give 2 -4 doses depending on karyotype and early MRD response, similar to patients with NDS-ALL. Whereas dexamethasone is given in induction to all DS patients in the UK, the COG gives it only to patients <10 years old and AIEOP-BFM (Italian-German consortium) to patients with T-cell phenotype and a good response to prednisolone pre-phase. There are no planned alterations in maintenance therapy except in the UK and in DS-ALL patients in COG protocols where the duration of maintenance has been shortened from 3 to 2 years for boys with DS-ALL, and with reduction in monthly vincristine/steroid pulses in COG protocols.
Interestingly, despite these variabilities in treatments, no significant differences in outcome were detected between the major therapeutic protocols of DS-ALL 7 .
Additional supportive care measures are recommended for DS-ALL patients by all groups ranging from antibiotic and antifungal prophylaxis during periods of neutropenia to intravenous immunoglobulin infusions to maintain IgG level above a defined threshold. However, there is no evidence of the efficacy of these measures in this setting and, for that reason, no consensus on the matter.
Facing the challenge -how best to treat (table 2)
Children with newly diagnosed ALL
• We strongly recommend that, like every other child with ALL, DS children should be treated on prospective treatment protocols. More than 70% of children with DS-ALL treated with such protocols will be cured.
• As DS-ALL is a high risk disease, we recommend avoidance of any dose reduction that is not specified in the protocol. Children with high risk criteria, e.g. high MRD should be treated according to high risk protocols.
• As poor adherence to dosing in maintenance has been shown to be associated with increased relapse in DS-ALL, We recommend that fear of infection should not deter clinicians from timely protocol specific dose escalations in patients with stable counts.
• The child with DS-ALL with TEL-AML1 or hyperdiploidy has excellent prognosis similar to NDS-ALL with most deaths due to toxicity 7 . For these children and probably for those with negative MRD at the end of induction, we recommend to consider treatment reduction in the face of moderate to severe toxicity.
• It should be emphasized that the risk of infectious related TRM is increased even during maintenance. Hence children with DS-ALL should be reviewed more frequently during both intensive and maintenance periods. Antibiotics
should be initiated at the earliest suspicion for infection even in the absence of neutropenia.
• Sensible approaches for preventing respiratory viral infections by limiting exposure and vaccinating family members against influenza are warranted.
• The role of prophylactic antibiotics is unclear, and the protocols we represent (COG, UK, Dutch and AIEOP-BFM) as well as our infectious disease specialists differ in their opinions. Some experts recommend ciprofloxacin prophylaxis during intensive treatment periods, or ampicillin for children with frequent respiratory viral infections.
• There is similar debate regarding antifungal prophylaxis, especially as there is no evidence for increased fungal infections in these patients.
• Hypogammaglobulinemia should be aggressively investigated and treated;
common recommendations for acquired hypogammaglobulinemia are to measure IgG monthly and treat with IVIG 0.5 g/kg every 3-4 weeks if levels drop below 4 g/l.
Approach for relapse / role of novel and emerging technologies
Treatment of Relapse. Despite children with relapsed DS-ALL having more favorable prognostic factors than relapsed NDS-ALL 52 , the prognosis of relapse of DS-ALL is grim. A recent study analyzing the outcome of 49 DS-ALL patients treated on the BFM relapse protocol 52 demonstrated only 17% long term survival, with TRM being the major factor determining the worse prognosis compared with NDS-ALL. There is a general reluctance to use SCT, as this therapy is considered to be too toxic.
Interestingly, however, of 18 patients transplanted in the PdL cohort, 6 were cured, 2 died from infections, one from GVHD and 9 from relapse , relapse and not TRM was the major reason for failure after SCT.
Hence SCT can be considered for DS-ALL patients in good general health, with good response to relapse induction chemotherapy. As CNS toxicity of total body irradiation (TBI) is a concern in DS, a radiation free approach should be considered as a preparatory regimen.
For We are indebted to Trudy Buitenkamp and physicians and investigators from the childhood ALL study protocols around the world studies that contributed information for this article.
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